Transaction Overview - Clearwater Analytics Holdings, Inc. has agreed to be acquired by a group of private equity funds at a price of $24.55 per share, which will result in shareholders being cashed out and the company's shares no longer being publicly traded [2]. Investigation Findings - The investigation by Kaskela Law LLC has revealed significant conflicts of interest in the transaction, suggesting that the proposed buyout price may be unfair to investors. Analysts had set price targets for Clearwater's shares at over $35.00, indicating a potential undervaluation of approximately 40% compared to the buyout price [3]. Legal Considerations - Kaskela Law is examining whether Clearwater's board of directors violated securities laws or breached fiduciary duties by agreeing to the buyout at a price significantly lower than analyst targets. Shareholders are encouraged to contact the firm to explore their legal rights and options before the transaction closes [4][7].

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the $5.80 per share buyout offer for European Wax Center, Inc. to determine if shareholders are receiving an adequate price for their shares [1][4]. Transaction Details - On February 10, 2026, European Wax announced its agreement to be acquired by General Atlantic at a price of $5.80 per share, after which the company's shares will no longer be publicly traded [2]. Investigation Findings - The investigation has revealed potential conflicts of interest in the transaction, suggesting that the proposed buyout price may be unfair to shareholders. An analyst had a price target of $15.00 per share for European Wax, indicating a discrepancy of over 150% compared to the buyout price [3]. Legal Considerations - Kaskela Law is examining whether the board of directors of European Wax violated securities laws or their fiduciary duties by agreeing to the buyout price, which is significantly lower than analyst targets. Shareholders are encouraged to contact the firm to explore their legal rights and options [4][7].

Group 1 - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Cogent Communications Holdings, Inc. and may file a class action on behalf of investors [1] - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and to join the case [1] - The firm offers complimentary case evaluations for investors seeking to recover losses [1] Group 2 - JPMorgan and RBC Capital seized $82 million in Cogent shares in August 2025, which were pledged as loan collateral by CEO Dave Schaeffer [2] - This seizure has led to an investigation into potential gross mismanagement by the Company's board of directors and possible breaches of fiduciary duties to shareholders [2] - The inquiry focuses on the board's oversight of executive compensation and pledging practices that resulted in the significant transfer of equity [2]

Core Viewpoint - Disc Medicine, Inc. is under investigation for potential violations of federal securities laws following the FDA's issuance of a Complete Response Letter (CRL) for its lead therapeutic candidate, bitopertin, which delays approval and impacts the company's valuation significantly [1][2][5]. Group 1: FDA Response and Impact - On February 13, 2026, the FDA issued a CRL for bitopertin, indicating that the application cannot be approved in its current form and requires additional data submissions [2]. - Bitopertin was positioned as a transformative therapy for approximately 4,000 Erythropoietic protoporphyria (EPP) patients in the U.S., and the CRL delays potential approval until at least 2027, eliminating near-term commercial revenue [3]. - Following the CRL announcement, Disc shares declined by 21.9%, reflecting the market's prior expectations of a favorable FDA outcome based on the company's communications [4]. Group 2: Investigation Focus - The investigation by Levi & Korsinsky is centered on whether Disc and its senior executives made statements regarding the regulatory prospects of bitopertin that did not fully disclose the risks and challenges faced in interactions with the FDA prior to the CRL [5].

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws, following allegations of misleading revenue growth claims related to its product ASCENIV [1][2]. Financial Performance - In Q4 2025, ADMA reported net revenue of $363 million for ASCENIV, marking a 51% year-over-year growth [2]. - However, a short report by Culper Research suggests that this growth may be attributed to "classic channel stuffing," raising concerns about the authenticity of the reported figures [2]. - The discrepancy between ADMA's claimed 20% revenue growth and the alleged 3% decline in underlying demand indicates a significant divergence in performance metrics [2]. Market Reaction - Following the release of the short-seller report on March 24, 2026, ADMA's stock experienced a sharp decline, reflecting investor concerns over the company's revenue reporting practices [2].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Gemini Space Station, Inc. for misrepresentations related to its Initial Public Offering and subsequent securities sales [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Gemini Class A common stock during its IPO on September 12, 2025, or acquired securities between September 12, 2025, and February 17, 2026 [1]. - Investors have until May 18, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Corporate Changes and Stock Performance - On February 5, 2026, Gemini announced a significant corporate pivot to "Gemini 2.0," which included a focus on its prediction market, a 25% workforce reduction, and exiting the UK, EU, and Australian markets [2]. - Following this announcement, Gemini's Class A common stock price fell by $0.64, or 8.72%, closing at $6.70 per share [2]. - On February 17, 2026, the company announced the departure of key executives and reported a 40% increase in operating expenses for 2025, leading to a further decline in stock price by $0.97, or 12.9%, closing at $6.585 per share [3]. - At the time of the lawsuit filing, Gemini's Class A common stock was trading at $5.96 per share, reflecting a 78.7% decline from its IPO price of $28.00 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Plug Power Inc. securities between January 17, 2025, and November 13, 2025, of the opportunity to lead a securities fraud lawsuit, with a deadline for lead plaintiff applications set for April 3, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding the likelihood of funds from the U.S. Department of Energy's Loan being available to Plug Power and the construction of necessary hydrogen production facilities [5]. - It is claimed that Plug Power was likely to shift towards less ambitious projects with lower commercial potential, which rendered the company's public statements materially false and misleading [5]. Group 2: Participation Information - Investors who purchased Plug Power securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6].

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported by investors during the specified class period [1][4]. Company Overview - Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems aimed at utility-scale commercial and industrial applications [3]. Allegations of the Lawsuit - The lawsuit claims that Eos Energy made false or misleading statements and failed to disclose critical operational issues, including: - Inability to achieve production and capacity utilization as per guidance [4]. - Battery line downtime exceeding industry norms and internal forecasts [4]. - Delays in automated bipolar production quality targets [4]. - Inadequate systems preventing accurate guidance and timely disclosures [4]. Financial Performance - On February 26, 2026, Eos Energy reported its fourth quarter and full year 2025 results, revealing: - Full year 2025 revenue of $114.2 million, significantly below the guidance of $150 million to $160 million [5]. - A gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million [5]. - An adjusted EBITDA loss of $219.1 million and a capacity milestone reached five weeks later than planned [5]. - Following this announcement, Eos Energy's stock price dropped by over 39% [5].

Core Viewpoint - Driven Brands Holdings Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial misstatements impacting its stock value [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Clark v. Driven Brands Holdings Inc., and it involves purchasers of Driven Brands common stock from May 9, 2023, to February 24, 2026 [1]. - Investors have until May 8, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Driven Brands and certain executives made false or misleading statements and failed to disclose critical financial errors [3]. Group 2: Allegations of Financial Misstatements - Allegations include errors in lease recording affecting right of use assets and liabilities as of December 28, 2024, and September 27, 2025 [3]. - There were inaccuracies in reporting cash balances and operating cash flows, leading to overstatements of cash and revenue for fiscal years 2023 and 2024 [3]. - Misclassification of supply and other expenses as company-operated store expenses was also reported for fiscal years 2023 and 2024 [3]. - Additional errors were identified related to income tax provisions, revenue recognition, and other financial misclassifications [3]. Group 3: Impact of Financial Disclosure - On February 25, 2026, Driven Brands disclosed material errors in its previously issued financial statements for fiscal years 2023 and 2024, leading to a nearly 40% drop in stock price [4]. Group 4: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Driven Brands common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [5]. Group 5: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [6].

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Weis Markets, Inc. following the company's announcement of a restatement of multiple audited financial statements due to overstated inventory, which has led to a significant drop in share price [1][2]. Group 1: Company Overview - Weis Markets, Inc. is facing scrutiny for allegedly issuing false or misleading statements and failing to disclose critical information to investors [2]. - The company disclosed in an SEC filing on February 26, 2026, that it would restate financial statements for previous years, which has raised concerns among shareholders [2]. Group 2: Financial Impact - Following the announcement of the restatement, shares of Weis Markets fell by nearly 7.2% on the same day [2]. - The company also indicated a delay in filing its 2025 annual report, further impacting investor confidence [2]. Group 3: Legal Action - The Schall Law Firm is encouraging affected shareholders to participate in the investigation and discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, indicating a focus on protecting investor interests [3].